Amy Childs

mom of 3 | family NP | oncology nurse passionate about health education, equity & access | ideas & opinions are my own

[Amy Childs @achildsrn]

@ThisIsTheWay75 @Mointhedeep84 @MeganFoxWriter @HouseofFluxx The women are with you

[OncLive.com @OncLive]

With routine NGS and IHC guiding diagnosis, clinicians compared real-world T-DXd experience with rising excitement around zongertinib data. ⭐

Explore how these findings may reshape frontline decisions: https://t.co/ijAEZTpUmp
#NSCLC

[The US Oncology Network @TheUSONetwork]

Physicians in The Network are leading the way on new #CancerResearch, including finding ways to make it more accessible. In this interview with @OncLive, Dr. Martin Dietrich discusses the research into zongertinib as a treatment for HER2 #NSCLC: https://t.co/N8h9nBWUUS

[Boehringer Ingelheim @boehringerus]

#NEWS: Our targeted therapy for HER2-mutant advanced non-small cell lung cancer has received a Commissioner’s National Priority Voucher from the U.S. FDA.

Learn more: https://t.co/vgHVJNqc5c

#LifeForward #Oncology

[Hagen Kennecke @HKennecke]

#NANETS25. Tumor DLL3 high (50%+) is a strong biomarker of response to #obrixtamig in epNECs. Large cohort of patients, congrats ⁦@Ja_Capdevila⁩ ét al.
⁦@NANETS1⁩ ⁦@boehringerus⁩

[Exon 20 Group, a multistakeholder organization @Exon20Group]

Oncologists treating HER2 lung cancer patients, please memorize one of the most important #ESMO25 takeaways: “Zongertinib for treatment-naive HER2 lung.” Eager to hopefully see a super fast approval via @FDAOncology And payers take note: Zongertinib exquisitely bends your cost curves down no matter when it is prescribed to HER2 lung patients. If there were a prize for Mildest Cancer Drug Ever, zongertinib would be a top contender!

[Stephen V Liu, MD @StephenVLiu]

#ESMO25 Zongertinib showing very promising 1L efficacy in Beamion LUNG-1 expertly presented by @DrSanjayPopat. Phase III 1L study (Beamion LUNG-2) ongoing, comparing zongertinib to SOC and kudos to this team for mandating crossover. Eager to see results. #ESMOAmbassadors

[CancerNetwork® @CancerNetwrk]

Front-line zongertinib achieved an ORR of 77%, with a CR rate of 8% and a PR rate of 69%, in patients with treatment-naïve advanced HER2-mutated NSCLC.

https://t.co/AHC5uOAS2E

#NSCLC #lcsm #ESMO25 | @DrSanjayPopat

[OncLive.com @OncLive]

Zongertinib in the 1L setting (#BEAMION LUNG-1 cohort 2) presented by @DrSanjayPopat showed significant, rapid clinical benefit in patients with untreated HER2-mutant NSCLC with an ORR of 77% and a DCR of 96%. Eagerly awaiting read out from the randomized 1L study (#BEAMION LUNG-2). As the treatment paradigm for HER-2 mut NSCLC evolves, proper biomarker-guided patient selection for treatment sequencing will be essential.

Great commentary from Dr Dingemans discussing the importance of characterizing adverse events in detail to capture the impact on patient quality of life as opposed to relying solely on investigator assessment and CTCAE, as well as the importance of clinical equipoise in ethical clinical trial design.

@JonathanWLee23
#Medtwitter
#Oncology
#CancerResearch
#ESMO25

[Boehringer Ingelheim @Boehringer]

#NEWS: New data for patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.  

These advancements have the potential to fulfill patients’ unmet needs.  

Learn more: https://t.co/0sQDs6DSsC

#LifeForward #Oncology

[Boehringer Ingelheim @boehringerus]

#NEWS: New data for HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) at #ESMO25.  

These advancements represent the potential for meaningful moments for this community.   

Learn more: https://t.co/GY7vaQ2U0D

#LifeForward #Oncology

[Heloisa Soares MD, PhD, FASCO @helops79]

So much progress in the treatment of neuroendocrine tumors 💙 The oncology brothers always make for great conversations! Thank you @OncBrothers @ProfKHerrmann @COR2EDMedEd

[Boehringer Ingelheim @boehringerus]

#NEWS: Our targeted therapy for HER2 (ERBB2)-mutant advanced #NSCLC was recommended in the @NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).  

Learn more: https://t.co/oxgmlsylV3

#Oncology #NSCLC #LifeForward

[Boehringer Ingelheim @boehringerus]

#NEWS: The U.S. FDA has approved our targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced #NSCLC! This is the first treatment of its kind for this patient population. #LungCancer

Learn more: https://t.co/sYodqjSxNG

[Boehringer Ingelheim @Boehringer]

#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the @US_FDA.

#LifeForward #Oncolog#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the @US_FDA.

#LifeForward #Oncolog#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the @US_FDA.

#LifeForward #Oncolog#NEWS for media: Our targeted cancer therapy has been approved in the U.S. for people with HER2 (ERBB2)-mutant advanced non-small cell lung cancer by the @US_FDA.

#LifeForward #Oncology

[AACR @AACR]

The @US_FDA granted accelerated approval to the HER2 inhibitor zongertinib for certain adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors harbored mutations in the tyrosine kinase domain of HER2: https://t.co/JNs00KncDT

[Oncology Brothers @OncBrothers]

Zongertinib (oral TKI) now @US_FDA approved based off #BeamionLung1 in previously treated metastatic NSCLC w/ HER2+:

- 71% ORR w/ 14.1mos mDoR
- mPFS 12.4%
- ≥Gr 3 AEs in less than 20%. Common AEs includied diarrhea and rash

#OncTwitter #MedTwitter

[LARVOL @Larvol]

Key lung cancer 🫁 milestones to watch in 2025.

🔗 Follow us for latest clinical trials and insights from the world of oncology 👉 https://t.co/MYJm2NGHs1

#LARVOL #LungCancer #WorldLungCancerDay #CancerResearch #Oncology #ClinicalTrials #CancerData #OncologyInsights #WLCD | @lungoncdoc | @ADesaiMD | @CharuAggarwalMD | @DrSanjayPopat | @DrRiyazShah | @GlopesMd | @StephenVLiu | @SuyogCancer

[Thor Halfdanarson @OncoThor]

Obrixtamig, a DLL3/CD3 IgG-like T-cell engager for SCLC and epNECs. Just out in JCO. Clearly efficacy in these hard-to-treat cancers and larger studies ongoing will hopefully confirm that.

https://t.co/mCDpVGRCxX

[Amy Childs @achildsrn]

@HosseinBorghaei What an incredible accomplishment! Congratulations!!